Figure 1.
Changes in clinical parameters with empagliflozin and dapagliflozin treatment: (A) hemoglobin (Hb) A1c, (B) systolic blood pressure (SBP), and (C) N-terminal prohormone of B-type natriuretic peptide (NT-proBNP).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.